drugset / Trial / NCT05527288

A Bridging Study on Efficacy and Safety of [18F]Florbetaben PET for Diagnosis of Alzheimer Disease Subjects in Chinese Population

NCT05527288

Completed 50 enrolled Sinotau Pharmaceutical Group
NaSingle-groupOpen-labelDiagnostic

Summary

This is a bridging study to visually and quantitatively assess PET images obtained after single application of 300 MBq \[18F\]florbetaben and PET scanning of patients with Alzheimer disease.

Timeline

Start
2021-01-28
Primary completion
2021-09-12
Completion
2021-09-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Florbetaben Diagnostic / imaging agent 300 mbq Intravenous